Drug intelligence / Profile preview

2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide

Development stage: Preclinical
Modality: Small Molecules

Overview

This compound is a small molecule inhibitor, specifically designed to target carbonic anhydrases. It has been studied for its potential in inhibiting tumor-associated carbonic anhydrase isoforms, such as CA IX and XII, which are involved in cancer progression. The compound's mechanism involves binding to these enzymes, thereby inhibiting their activity and potentially reducing tumor growth.

Other names: 2-(Hydrazinocarbonyl)-3-phényl-1H-indole-5-sulfonamide2-(Hydrazinocarbonyl)-3-phenyl-1H-indol-5-sulfonamid

Targets

CA12 (Carbonic anhydrase XII)CA9 (Carbonic anhydrase IX)CA2 (Carbonic Anhydrase 2)CA14 (Carbonic Anhydrase 14)CA1 (Carbonic anhydrase 1)CA7 (Carbonic anhydrase VII)

Beyond the preview

Go deeper on 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide.

Explore the full profile